Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study by Maisel, Alan S. et al.
 
 
 University of Groningen
Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure
Hospitalizations
Maisel, Alan S.; Wettersten, Nicholas; van Veldhuisen, Dirk J.; Mueller, Christian; Filippatos,
Gerasimos; Nowak, Richard; Hogan, Christopher; Kontos, Michael C.; Cannon, Chad M.;
Mueller, Gerhard A.
Published in:
Journal of the American College of Cardiology
DOI:
10.1016/j.jacc.2016.06.055
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Maisel, A. S., Wettersten, N., van Veldhuisen, D. J., Mueller, C., Filippatos, G., Nowak, R., Hogan, C.,
Kontos, M. C., Cannon, C. M., Mueller, G. A., Birkhahn, R., Clopton, P., Taub, P., Vilke, G. M., McDonald,
K., Mahon, N., Nunez, J., Briguori, C., Passino, C., & Murray, P. T. (2016). Neutrophil Gelatinase-
Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS
Study. Journal of the American College of Cardiology, 68(13), 1420-1431.
https://doi.org/10.1016/j.jacc.2016.06.055
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020




J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 8 , N O . 1 3 , 2 0 1 6
ª 2 0 1 6 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N
P U B L I S H E D B Y E L S E V I E R
I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 6 . 0 6 . 0 5 5Neutrophil Gelatinase-Associated
Lipocalin for Acute Kidney Injury During
Acute Heart Failure Hospitalizations
The AKINESIS StudyAlan S. Maisel, MD,a,b Nicholas Wettersten, MD,b Dirk J. van Veldhuisen, MD,c Christian Mueller, MD,d
Gerasimos Filippatos, MD,e Richard Nowak, MD,f Christopher Hogan, MD,g Michael C. Kontos, MD,h
Chad M. Cannon, MD,i Gerhard A. Müller, MD, PHD,j Robert Birkhahn, MD,k Paul Clopton, MS,a Pam Taub, MD,b
Gary M. Vilke, MD,l Kenneth McDonald, MD,m,n Niall Mahon, MD,n,o Julio Nuñez, MD,p Carlo Briguori, MD, PHD,q











CoBACKGROUND Worsening renal function (WRF) often occurs during acute heart failure (AHF) and can portend adverse
outcomes; therefore, early identification may help mitigate risk. Neutrophil gelatinase-associated lipocalin (NGAL) is a
novel renal biomarker that may predict WRF in certain disorders, but its value in AHF is unknown.
OBJECTIVES This study sought to determine whether NGAL is superior to creatinine for prediction and/or prognosis of
WRF in hospitalized patients with AHF treated with intravenous diuretic agents.
METHODS This was a multicenter, prospective cohort study enrolling patients presenting with AHF requiring intrave-
nous diuretic agents. The primary outcome was whether plasma NGAL could predict the development of WRF, defined as
a sustained increase in plasma creatinine of 0.5 mg/dl or $50% above first value or initiation of acute renal-replacement
therapy, within the first 5 days of hospitalization. The main secondary outcome was in-hospital adverse events.
RESULTS We enrolled 927 subjects (mean age, 68.5 years; 62% men). The primary outcome occurred in 72 subjects
(7.8%). Peak NGAL was more predictive than the first NGAL, but neither added significant diagnostic utility over the
first creatinine (areas under the curve: 0.656, 0.647, and 0.652, respectively). There were 235 adverse events in 144
subjects. The first NGAL was a better predictor than peak NGAL, but similar to the first creatinine (areas under the curve:
0.691, 0.653, and 0.686, respectively). In a post hoc analysis of subjects with an estimated glomerular filtration
rate <60 ml/min/1.73 m2, a first NGAL <150 ng/ml indicated a low likelihood of adverse events.
CONCLUSIONS Plasma NGAL was not superior to creatinine for the prediction of WRF or adverse in-hospital outcomes.
The use of plasma NGAL to diagnose acute kidney injury in AHF cannot be recommended at this time. (Acute Kidney
Injury Neutrophil Gelatinase-Associated Lipocalin [N-GAL] Evaluation of Symptomatic Heart Failure Study [AKINESIS];
NCT01291836) (J Am Coll Cardiol 2016;68:1420–31) © 2016 by the American College of Cardiology Foundation.m the aDivision of Cardiovascular Medicine, Veterans Affairs Medical Center, San Diego, La Jolla, California; bDivision of
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AB BR E V I A T I O N S
AND ACRONYM S
AHF = acute heart failure
AKI = acute kidney injury
AUC = area under the curve
BUN = blood urea nitrogen
CI = confidence interval
eGFR = estimated glomerular
filtration rate
HF = heart failure
IV = intravenous
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1421H eart failure (HF) is a major global healthproblem, with more than 23 million peopleafflicted worldwide (1). Kidney dysfunction
is common among patients hospitalized with acute
HF (AHF) and portends a worse prognosis (2–4). A
strong interaction is recognized between the heart
and kidney, and worsening renal function (WRF)
can occur with treatment of AHF with adverse out-
comes (5,6). Creatinine is currently the standard
biomarker for renal function; however, it has a
delayed increase after kidney injury. Furthermore,
WRF in AHF, reflected by a rise in creatinine, may
not reflect acute kidney injury (AKI) and may not be
prognostic in all patients (7). Novel biomarkers are
needed for earlier detection of WRF that is associated
with adverse outcomes (8).SEE PAGE 1432
WRF = worsening renal
functionNeutrophil gelatinase-associated lipocalin (NGAL)
is a small molecule of the lipocalin family of proteins.
Found on the brush-border of renal tubular cells,
NGAL increases during the acute phase of toxic and
ischemic kidney injury (9). Plasma NGAL has predic-
tive value for AKI in multiple conditions, including
cardiac surgery, contrast-induced nephropathy, and
critical illness (10–12). It is also elevated in patients
with chronic HF and is associated with adverse out-
comes, but its value in patients with AHF is not well
established (13,14). Single-center studies have sug-
gested that NGAL predicts WRF in AHF; however, it is
unknown if this can be reproduced on a larger scale,
or if NGAL is specifically useful with intravenous (IV)
diuretic therapy (15–17).
AKINESIS (Acute Kidney Injury N-gal Evaluation of
Symptomatic heart faIlure Study) is an international,
multicenter, prospective cohort study enrolling pa-
tients presenting with AHF. A primary goal was to
examine plasma NGAL’s ability to predict WRF or
need for renal-replacement therapy (RRT) in patients
with AHF treated with diuretic agents. A secondaryof Cardiology, Hospital Clínico Universitario Valencia, University of Valencia
Mediterranea, Naples, Italy; and the rDepartment of Cardiology and Cardiov
Pisa, Italy. Abbott Laboratories (Chicago, Illinois) and Alere (San Diego, Califo
design of the study, data management, and study oversight. The sponsors
paper or in preparation, review, or approval of the paper. Dr. Maisel previou
and Alere; and previously served as a consultant and speaker for Abbott Labo
grants and speakers/consulting honoraria from several diagnostic companie
and Provencio. Dr. Cannon has received institutional research support from
advisory board of Protagen Protein Service, PPS, Germany; and has a
Dr. Birkhahn has received a grant from Alere. Dr. Murray has received resear
has served as consultant for Abbott Laboratories. All other authors have rep
contents of this paper to disclose. Inder Anand, MD, DPhil (Oxon), served a
Manuscript received April 29, 2016; revised manuscript received June 19, 20goal was to assess prognostic ability for in-
hospital adverse outcomes.
METHODS
STUDY DESIGN. AKINESIS was an interna-
tional, multicenter, prospective cohort study
enrolling patients presenting to the emer-
gency department or hospital with signs and
symptoms of AHF, with planned admission
and treatment with diuretic agents. Abbott
Laboratories and Alere, Inc., jointly spon-
sored the study. Subjects were enrolled at 16
sites, 7 in the United States and 9 in Europe,
and followed to discharge (NCT01291836).
The principal investigators and sponsors
designed and oversaw the trial. Each center’s
institutional review board approved the
study. All participants provided written informed
consent. Data were collated at a core data manage-
ment facility. The principal investigators had full ac-
cess to the database. An independent biostatistician
performed statistical analysis. The initial manuscript
was written by the first 2 authors, and reviewed and
edited by all authors. All authors vouch for the ac-
curacy of the reported findings.
PARTICIPANTS. Subjects at least 18 years of age,
presenting to the emergency department or hospital
with AHF, were screened for inclusion and enrolled as
early as possible. Subjects had to have 1 or more signs
or symptoms of HF, including dyspnea on exertion,
rales or crackles, galloping heart rhythm, jugular
venous distention, orthopnea, paroxysmal nocturnal
dyspnea, using more than 2 pillows to sleep, fatigue,
edema, frequent coughing, a cough that produces
mucous or blood-tinged sputum, or a dry cough when
lying flat. In addition, subjects must have received or
planned treatment with IV diuretic agents. Subjects
had to be able to comply with all aspects of the pro-
tocol and give consent., Valencia, Spain; qDepartment of Cardiology, Clinica
ascular Medicine, Fondazione Gabriele Monasterio,
rnia) funded the study. The sponsors assisted in the
did not participate in the analysis presented in this
sly received grant funding from Abbott Laboratories
ratories and Alere. Dr. Mueller has received research
s. Dr. Kontos is a consultant for Roche, AstraZeneca,
Abbott and Alere. Dr. Müller is a member of the
financial relationship with Celgene and Novartis.
ch funding from Abbott Laboratories and Alere; and
orted that they have no relationships relevant to the
s Guest Editor for this paper.
16, accepted June 28, 2016.
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1422Subjects were excluded if: 1) symptoms consistent
with acute coronary syndrome were the chief cause of
the current AHF episode; 2) they were already on
dialysis before enrollment or if dialysis initiation
was planned during the current hospitalization;
3) they had a heart, lung, kidney, or liver transplant;
4) they had participated in a drug treatment
study within the past 30 days or had already enrolled
in this study; or 5) they were pregnant or belonging to
an institutional review board–determined vulnerable
population.
ENDPOINTS. The primary outcome was whether
plasma NGAL predicted the development of either
WRF, reflected by a sustained increase in creatinine
of $0.5 mg/dl (44.2 mmol/l) or $50% of the first
creatinine value obtained, or the initiation of acute
RRT within 5 days of being hospitalized. A sustained
increase was defined as a creatinine value meeting
criteria on at least 2 consecutive days. Acute RRT
modalities included dialysis, ultrafiltration, and
hemofiltration. The predictive ability of NGAL for
each endpoint of WRF and RRT was also tested.
The major secondary endpoint was the ability of
NGAL to predict adverse in-hospital outcomes. These
included severe WRF (a sustained increase $100% of
the first creatinine value); initiation of RRT; death;
nephrology consultation; and admission to the
intensive care unit with need for mechanical venti-
lation, inotropic/vasopressor support, or both.
Pre-specified secondary endpoints included
whether an elevated NGAL on admission predicted
which subjects with an admission estimated glomer-
ular filtration rate (eGFR) <60 ml/min/1.73 m2 would
have a greater decrease in eGFR at discharge. Pre-
specified alternative definitions of WRF included
a sustained increase in creatinine $0.3 mg/dl
(26.5 mmol/l) or $50% of the first creatinine, and a
sustained increase in creatinine $50% of the first
creatinine, both during the first 5 days of hospitali-
zation. Although the latter definition is similar to RI-
FLE (Risk, Injury, Failure, Loss of kidney function,
and End-stage kidney disease) criteria, the KDIGO
(Kidney Disease: Improving Global Outcomes) criteria
for AKI, which are similar to AKIN (Acute Kidney
Injury Network) criteria, were published during study
enrollment. This definition did not use a sustained
increase in creatinine; thus, post hoc analyses without
sustained increases were performed. These included a
nonsustained increase of $0.5 mg/dl or $50% of
the first creatinine and a nonsustained increase in
creatinine of $0.3 mg/dl or $50% of the first creati-
nine, both during the first 5 days of hospitalization,
and any nonsustained increase of $0.3 mg/dl or$50% of the first creatinine at any time during the
hospitalization.
Another post hoc analysis, prompted by an evolu-
tion in published reports on the evaluation of novel
renal biomarkers during the study, tested the pre-
dictive value of NGAL stratified by admission eGFR
and first NGAL for the combined endpoint of in-
hospital adverse outcomes (8). eGFR was stratified
at 60 ml/min/1.73 m2. NGAL was assessed using 2
cutpoints: the 80% sensitivity cutpoint, on the basis
of our analysis, and at 150 ng/dl, on the basis of a
prior study (11).
The primary predictive metric was the peak NGAL
value. The predictive value of the first NGAL, first
creatinine, and the combination of the first creatinine
and first NGAL were also analyzed. Peak NGAL was
defined as the highest value obtained at least 6 h
before the event, if the event time was available, or at
least a day before the event, if only the event date was
available. If the event occurred on the first day, or the
only available NGAL value was within 6 h of the
event, this was used. If an NGAL value was only
available after the event occurred, this was not used.
This peak value for subjects with an outcome was
compared with the peak value from all collected sam-
ples in subjects without the outcome. The first NGAL
was the value obtained only at the first collection time.
The first creatinine was the first value obtained.
DATA COLLECTION. After subjects were screened
and gave written consent, demographics, vital signs,
HF signs and symptoms on presentation, medica-
tions, and past medical history were collected. Lab-
oratory samples were collected as per standard of care
determined by the treating physician, and were
analyzed at the clinical laboratories of the treating
hospital. If collected, values recorded on admission
and discharge included white blood cell count, he-
moglobin, hematocrit, sodium, potassium, blood urea
nitrogen (BUN), creatinine, alanine aminotransferase,
aspartate aminotransferase, troponin, and natriuretic
peptides.
During the hospitalization, sodium, potassium,
BUN, and creatinine values were recorded for at least
the first 7 days of hospitalization. These were ob-
tained at the discretion of the treating physician. In-
hospital adverse outcomes listed previously were
recorded.
NGAL ASSESSMENT. Specimens for NGAL assess-
ment were collected at 6 time points if the subject
remained hospitalized during the collection period.
The first specimen was collected the day of enroll-
ment, within 2 h of the first IV diuretic dose.
The second specimen was collected 2 to 6 h later.
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1423The third, fourth, and fifth specimens were collected
on hospital day 1, 2, and 3, respectively. The sixth
specimen was collected on the day of discharge or
anticipated discharge. Compliance with sample
collection was high, except for the discharge sample,
with 98.3%, 92.0%, 94.7%, 96.7%, 94.5%, and 65.4%
of samples collected at the listed time points. Plasma
NGAL specimens were frozen and shipped to the core
laboratory for analysis with the Alere Triage plasma
NGAL assay.
STATISTICAL ANALYSES. Assuming an event rate of
9% and an area under the curve (AUC) of 0.70 for NGAL
for the primary outcome, it was estimated that 60
primary events had to occur to have 80% power to
detect a difference of 0.10 in AUC. With a 20% margin
of error, anticipated enrollment was 800 subjects;
however, as enrollment neared 800, the event rate was
lower than anticipated. It was decided to continue
enrollment until at least 60 events had occurred,
resulting in 930 subjects enrolled. The institutional
review boards were notified of the planned increase
and no site exceeded its enrollment limit.
Baseline variables are presented as means and
standard deviations for normally distributed contin-
uous variables, medians with interquartile ranges
for nonnormalized variables, and percentages for
categorical variables. When the status of a comor-
bidity was unknown, it was assumed to not be
present.
Baseline characteristics between subjects with and
without the primary outcome were compared using
the Student t test, chi-square test, and Mann-Whitney
U test, as appropriate. To explore the independent
predictive value of NGAL and potential influence of
covariates on the primary outcome, univariable lo-
gistic regression analysis was used. Variables with a
p value <0.10 were retained for forward, stepwise,
multivariate logistic regression analyses, and those
with a p value <0.05 were retained for a multivariate
model. The log-transformed values of peak and first
NGAL were added separately to the model, and the C
statistic was calculated with and without NGAL.
When NGAL and creatinine were assessed in combi-
nation, logistic regression was used and predictors
were log-transformed. Receiver operating character-
istic curves were generated to determine the AUC
with 95% confidence intervals (CIs) for peak NGAL,
first NGAL, first creatinine, and combined first NGAL
and first creatinine for the primary and secondary
outcomes. Cutpoints for 80% sensitivity and 80%
specificity were determined. Kaplan-Meier curves
were created for time to events of the primary and
combined secondary endpoint. Spearman correlationwas used to assess change in subjects with eGFR
<60 ml/min/1.73 m2 and NGAL values. Subgroups
were compared by chi-square test, and sensitivity,
specificity, and positive and negative predictive
values in the specific subgroups were calculated.
A p value <0.05 was considered significant. All sta-
tistical calculations were performed on SPSS version
19 (SPSS, Inc., Chicago, Illinois).
RESULTS
PATIENT DEMOGRAPHICS. From January 2011
through September 2013, a total of 930 subjects were
enrolled. One subject was later found not to meet
inclusion criteria, 1 met exclusion criteria, and 1
withdrew consent, leaving 927 subjects for analysis.
All subjects had follow-up throughout hospitaliza-
tion. Subjects were hospitalized for a median of
5 days (interquartile range: 6 days).
The mean age of subjects was 68.5 years, with 62%
men and 66.9% identified as white (Table 1). Most
subjects had hypertension (80.7%), a significant
portion had coronary artery disease (46.1%) and
diabetes mellitus (43.6%), and almost 26% had
chronic kidney disease. The median admission
creatinine was 1.19 mg/dl, with a median eGFR of
57 ml/min/1.73 m2. The median admission B-type
natriuretic peptide and N-terminal pro-B-type natri-
uretic peptide values were 795 pg/dl and 3,446 pg/dl,
respectively. Approximately 70% of subjects were on
diuretic agents before admission, 70% were on beta-
blockers, and almost 63% were on an angiotensin-
converting enzyme inhibitor or angiotensin-receptor
blocker.
PRIMARY OUTCOME. Seventy-two subjects (7.8%)
had the primary outcome (Figure 1A), with 66 (7.1%)
subjects having WRF and 11 (1.2%) requiring RRT.
Subjects with and without the primary outcome were
similar, except that subjects with the primary
outcome had a higher prevalence of diabetes and
chronic kidney disease (Table 1). The latter was re-
flected by significantly higher admission creatinine,
lower eGFR, and higher BUN. Hemoglobin was also
significantly lower. Troponin T was significantly
higher in subjects with the primary outcome, whereas
troponin I was not different.
A total of 918 subjects had peak NGAL values (9
subjects did not have any samples for NGAL analysis),
and 911 had first NGAL values (16 lacked a sample
from the first collection time). Peak values occurred a
mean of 1.6  1.1 days before the primary outcome,
with most events occurring 24 h after admission
(Figure 1A). Distributions of peak NGAL and first NGAL
TABLE 1 Baseline Characteristics of Study Patients and Comparison of Those With and Without Primary Outcome
N Total Primary Outcome No Primary Outcome
Age, yrs 921 68.5 (54.7–82.3) 70.75 (57.1–84.4) 68.3 (54.4–82.1)
Male 927 62.0 52.8 62.8
White 921 66.9 65.3 67.0
Systolic blood pressure, mm Hg 927 139.9 (110.8–169) 145.5 (115.8–175.2) 139.4 (110.4–168.3)
Diastolic blood pressure, mm Hg 927 80.1 (60.8–99.4) 82.1 (59.7–104.5) 79.9 (60.9–99)
Heart rate, beats/min 927 88 (65.2–110.8) 87 (68.3–105.7) 88 (64.9–111.2)
Past medical history
Acute myocardial infarction 927 27.5 29.2 27.4
Coronary artery disease 927 46.1 54.2 45.4
Prior PCI 927 22.5 26.4 22.2
Prior CABG 927 17.0 25.0 16.4
Arrhythmia 927 47.7 44.4 48.0
Hypertension 927 80.7 87.5 80.1
Hyperlipidemia 927 52.4 52.8 52.4
Diabetes* 927 43.6 58.3 42.3
Cerebrovascular accident 927 13.9 8.3 14.4
Peripheral arterial disease 927 3.2 2.8 3.3
COPD 927 26.1 23.6 26.3
Chronic kidney disease† 927 25.9 45.8 24.2
Anemia 927 22.4 29.2 21.9
Liver failure 927 2.8 5.6 2.6
Tobacco use 927 16.6 12.5 17.0
Cancer 927 14.1 13.9 14.2
Prior medications
Beta-blockers 927 70.2 73.6 69.9
ACE inhibitors 927 43.7 38.9 44.1
Angiotensin-receptor blockers 927 18.9 26.4 18.2
Diuretic agents 927 70.7 68.1 70.9
Antiarrhythmic agent 927 15.3 18.1 15.1
Digoxin 927 11.0 6.9 11.3
Laboratory studies
Sodium, mg/dl 921 139 [136–141] 139 [136–142] 139 [136–141]
Creatinine, mg/dl† 927 1.19 [0.94–1.6] 1.60 [1.02–2.46] 1.17 [0.93–1.55]
eGFR, ml/min/1.73 m2† 927 57.0 [40.4–77.8] 38.1 [24.8–66.1] 58.1 [42.4–79.2]
Hemoglobin, g/dl† 924 11.8 [10.1–13.2] 10.4 [8.7–12.4] 11.9 [10.3–13.3]
BUN, mg/dl† 918 23.5 [16.5–36.0] 33.7 [21.3–60.8] 23 [16–35]
BNP, ng/l 529 795 [337–1,486] 810 [501–1,915] 793 [328–1,479]
NT-proBNP, ng/l 316 3,446 [1,552–7,376] 4,814 [2,389–7,567] 3,221 [1,507–7,360]
Troponin T, ng/ml* 343 0.029 [0.015–0.056] 0.045 [0.024–0.080] 0.027 [0.014–0.051]
Troponin I, ng/ml 479 0.04 [0.02–0.07] 0.04 [0.025–0.115] 0.04 [0.02–0.066]
Values are mean (range), %, or median [interquartile range]. *p < 0.01. †p < 0.001.
ACE ¼ angiotensin-converting enzyme; AKI ¼ acute kidney injury; BNP ¼ B-type natriuretic peptide; BUN ¼ blood urea nitrogen; CABG ¼ coronary artery bypass graft;
COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular filtration rate; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; PCI ¼ percutaneous
coronary intervention.
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1424values for subjects with and without the primary
outcome are shown in Figure 1B.
For the primary outcome, the AUC, 80% sensi-
tivity cutpoint, and 80% specificity cutpoint for
peak NGAL were 0.656 (95% CI: 0.589 to 0.723),
141.0 ng/dl, and 350.0 ng/dl, respectively (Figure 2A).
The AUC, 80% sensitivity cutpoint, and 80% speci-
ficity cutpoint for first NGAL were 0.647 (95% CI:
0.579 to 0.715), 104.4 ng/dl, and 274.9 ng/dl,
respectively. In comparison, the AUC for the firstcreatinine value was 0.652 (95% CI: 0.576 to 0.729).
The combination of first creatinine and first NGAL
did not enhance predictive ability (AUC: 0.66;
95% CI: 0.586 to 0.733).
In multivariate logistic regression analysis,
admission systolic blood pressure, pre-existing
chronic kidney disease, admission hemoglobin, and
admission BUN retained significance in the model. No
interaction was found by region (United States vs.
Europe). Peak NGAL (p ¼ 0.038) was significant when
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(A) Kaplan-Meier curve with subjects at risk at the bottom. Approximately 86% of subjects
were free from the primary outcome at 5 days. (B) Peak and first NGAL values are displayed
in those with and without the primary outcome. NGAL values were log-transformed for
nonnormalized distribution. NGAL ¼ neutrophil gelatinase-associated lipocalin.
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1425added to the multivariate model, but the first NGAL
(p ¼ 0.071) was not. Findings did not differ on the
basis of region. The addition of peak NGAL did not
significantly improve the C statistic of the model
(AUC increased from 0.707 to 0.711; p ¼ 0.70) for the
primary outcome.
For the individual outcome of WRF, the AUCs for
peak NGAL, first NGAL, first creatinine, and combined
first NGAL and creatinine were 0.637 (95% CI: 0.566 to
0.708), 0.625 (95% CI: 0.554 to 0.695), 0.631 (95% CI:
0.552 to 0.711), and 0.636 (95% CI: 0.559 to 0.713),
respectively. For the individual outcome of RRT, the
AUCs for peak NGAL, first NGAL, first creatinine, and
combined first NGAL and creatinine were 0.884
(95% CI: 0.796 to 0.961), 0.902 (95% CI: 0.827 to
0.976), 0.876 (95% CI: 0.754 to 0.998), and 0.914
(95% CI: 0.827 to 1.00), respectively.
SECONDARY OUTCOMES. A total of 235 adverse out-
comes occurred in 144 subjects (Figure 3A). The dis-
tribution of peak NGAL value for subjects with each
adverse outcome and those without adverse outcomes
are shown in Figure 3B. The most common adverse
outcome was nephrology consultation (n ¼ 59). A sig-
nificant number of subjects were admitted to the
intensive care unit requiring inotropic/vasopressor
support (n¼ 51) or ventilator support (n¼ 43). Twenty-
nine subjects (3.1%) died during hospitalization.
The AUC, 80% sensitivity cutpoint, and 80%
specificity cutpoint for peak NGAL for the composite
secondary outcome were 0.653 (95% CI: 0.601 to
0.704), 124.6 ng/dl, and 331.6 ng/dl, respectively
(Figure 3C). AUC, 80% sensitivity cutpoint, and 80%
specificity cutpoint for the first NGAL were 0.691
(95% CI: 0.643 to 0.740), 109.3 ng/dl, and 247.5 ng/dl,
respectively. AUC for the first creatinine value was
0.686 (95% CI: 0.634 to 0.738). The combination of
first creatinine and first NGAL had an AUC of 0.716
(95% CI: 0.666 to 0.766). Because nephrology
consultation was the most frequent adverse outcome,
an analysis without this outcome was performed.
AUCs for peak NGAL, first NGAL, and first creatinine
notably decreased, and were 0.595 (95% CI: 0.534 to
0.656), 0.645 (95% CI: 0.589 to 0.701), and 0.623
(95% CI: 0.562 to 0.684), respectively.
The alternative definitions of WRF evaluated
included a sustained increase of creatinine $50% of
the first creatinine value, a nonsustained increase of
creatinine of $0.5 mg/dl or $50% of the first creati-
nine value, a sustained increase of creatinine of $0.3
mg/dl or $50% of the first creatinine value, and a
nonsustained increase of creatinine of $0.3 mg/dl
or $50% of the first creatinine value, occurring in the
first 5 days, and a nonsustained increase of creatinine
of $0.3 mg/dl or $50% of the first creatinine value atany time. For these definitions, there were 38 (4.1%),
112 (12.1%), 128 (13.8%), 222 (23.9%), and 284 (30.6%)
events, respectively. Using the first NGAL, AUCs
ranged from 0.488 to 0.625, with the highest AUC for
a nonsustained increase in creatinine of $0.3 mg/dl
or $50% of the first creatinine value at any time.
Evaluating peak NGAL value only in subjects whose
creatinine rose by $0.3 mg/dl, AUCs ranged from
0.593 to 0.606. Again, the highest AUC was in
those with a nonsustained increase in creatinine of
$0.3 mg/dl or $50% of the first creatinine value at any
time. In subjects with an eGFR <60 ml/min/1.73 m2,
there was no correlation between first NGAL and
percent decline in eGFR at discharge.











































































Peak NGAL First NGAL First Creatinine
Receiver operating characteristic curves for primary outcome (A), individual components of worsening renal function (B), and renal-
replacement therapy (C). Each plot contains receiver operating characteristic for peak NGAL, first NGAL, and first creatinine, as well as AUC with
95% CIs. AUC ¼ area under the curve; CI ¼ confidence interval; NGAL ¼ neutrophil gelatinase-associated lipocalin.
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1426SUBGROUP ANALYSIS. Subjects were first stratified
by eGFR greater or less than 60 ml/min/1.73 m2.
Subsequently, they were stratified at 2 cutpoints of
the first NGAL: NGAL greater or less than 150 ng/dl,
and greater or less than 109.3 ng/dl, the latter being
the 80% sensitivity cutpoint for the composite sec-
ondary outcome. The percent of subjects who had any
adverse outcome, by the different subgroups and
NGAL cutpoints, is shown in Figure 4A.
The occurrence of adverse events increased with
increasing NGAL and decreasing eGFR. Subjects witheGFR $60 ml/min/1.73 m2 and NGAL less than the
cutpoint had the fewest adverse outcomes, followed
by those with eGFR <60 ml/min/1.73 m2 and NGAL
less than the cutpoint, then eGFR $60 ml/min/1.73 m2
and NGAL greater than the cutpoint, and, lastly, those
with eGFR <60 ml/min/1.73 m2 and NGAL greater than
the cutpoint, who had a marked increase in adverse
outcomes (Figures 4B and 4C). In subjects with an
eGFR <60 ml/min/1.73 m2 and NGAL less than the
cutpoint, a cutpoint of 150 ng/dl had 84.5% sensitivity
and a 91.0% negative predictive value for excluding
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(A) Kaplan-Meier curve for the combined secondary outcome with subjects at risk is at the bottom. Approximately 50% of subjects at risk for an adverse
event experienced an event during hospitalization. (B) Peak NGAL values (log-transformed) for the individual components of the combined secondary
outcome are shown. (C) Receiver operating characteristic curves for the combined secondary outcome with peak NGAL, first NGAL, and first creatinine AUC
and 95% CI. ino ¼ inotrope/vasopressor; Neph Con¼ nephrology consultation; RRT ¼ renal-replacement therapy; Vent¼ ventilator; WRF ¼worsening renal
function; other abbreviations as in Figure 2.
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1427the development of an adverse outcome, whereas a
cutpoint of 109.3 ng/dl had a 90.3% sensitivity and
91.1% negative predictive value (Figures 4B and 4C).
DISCUSSION
WRF during hospitalization for AHF is associated
with significant morbidity and mortality (2–4,6). Both
mechanistic and iatrogenic perturbations are causa-
tive, including diuretic therapy, with its neurohor-
monal activation and maladaptive effects on renal
function (18,19). Although serum creatinine is
considered the standard functional biomarker for
diagnosing WRF, it often does not increase until 1 to 3days after injury has occurred, delaying diagnostic
assessment and potential management. Thus, there is
a clear unmet need for biomarkers to diagnose WRF
earlier during the treatment of AHF, to potentially
prevent or ameliorate progressive kidney damage and
dysfunction.
AKINESIS is one of the largest multicenter inter-
national trials exclusively evaluating the role of bio-
markers for predicting the development of WRF or
renal dysfunction requiring RRT in patients present-
ing with AHF treated with diuretic agents. More spe-
cifically, in this report, we examined a commercially
available biomarker, plasma NGAL. Although analysis
demonstrated a potential role for plasma NGAL in
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Adverse Events by eGFR and NGAL 109.3
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(A) Percent of subjects with an adverse event stratified by eGFR and the 2 different NGAL cutpoints. Incidence of adverse events by subgroups of eGFR (B)
and NGAL (C), presented by increasing prevalence of events, with their respective sensitivities, specificities, positive predictive values, and negative pre-
dictive values displayed beside them. eGFR ¼ estimated glomerular filtration rate; GFR ¼ glomerular filtration rate; other abbreviations as in Figure 2.
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CENTRAL ILLUSTRATION Potential Diagnostic
Algorithm for Neutrophil Gelatinase-Associated
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Maisel, A.S. et al. J Am Coll Cardiol. 2016;68(13):1420–31.
In patients presenting with AHF treated with intravenous diuretic agents,
the results of AKINESIS do not support the use of NGAL in patients
with an eGFR $60 ml/min/1.73 m2. However, in patients with an
eGFR <60 ml/min/1.73 m2, NGAL may identify patients at low risk for
adverse events. The proposed algorithm is the result of subgroup analysis
and requires further study for confirmation. AHF ¼ acute heart failure;
AKINESIS ¼ Acute Kidney Injury N-gal Evaluation of Symptomatic heart
faIlure Study; eGFR ¼ estimated glomerular filtration rate;
NGAL ¼ neutrophil gelatinase-associated lipocalin.
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1429predicting adverse outcomes, this was driven by
nephrology consultation, and NGAL could not predict
the development of WRF better than creatinine. There
are several possible reasons why NGAL was not
significant.
First, WRF may be caused by multiple factors,
including AHF therapies; concurrent illness; or car-
diorenal syndrome, a complex state consisting of
multiple pathophysiologic processes (5,20). AKINESIS
was designed to assess early development of WRF
with diuretic therapy; however, we could not
adequately assess other possible etiologies of WRF, or
if WRF developed later during the hospital course or
before presentation. Other, unaccounted factors may
have contributed to the rise in NGAL or the develop-
ment of WRF. NGAL has been associated with car-
diovascular disease and may be a marker of disease
severity (21). This association with disease severity
may be reflected in our clinical composite secondary
outcome.
Second, the definition and understanding of what
constitutes AKI is changing (22,23). Renal injury can
occur to varying degrees at different sites of the
kidney and by multiple different mechanisms. WRF
may be manifested as renal damage, functional
change (classically termed pre-renal AKI), or both
(classically termed acute tubular necrosis), with
biomarkers of kidney damage or dysfunction
detecting different types of renal injury (24). It
seems that NGAL may not detect renal injury re-
flected by an increase in creatinine imposed by
diuretic therapy (7). In a prior small study, NGAL did
not change with the withdrawal and reinstitution of
diuretic therapy (25).
Third, the rate of WRF in AKINESIS was low, at
7.1%, compared with prior studies of NGAL, which
have reported rates of 11.8% to 33.8%; however, a
more liberal definition of a creatinine increase
$0.3 mg/dl was used to define WRF in these studies
(15,16). The low rate of WRF likely stems from our
more stringent definition of WRF. Using an increase
of $0.3 mg/dl as a definition, 30.6% patients devel-
oped WRF in our cohort. Even with this definition,
the predictive value of NGAL was low. Notably,
NGAL’s predictive ability improved with increasing
severity of kidney injury, as previously reported (26).
NGAL did have fair prognostic ability for adverse in-
hospital outcomes (AUC: 0.691), although this was
similar to creatinine (AUC: 0.686), and was driven by
nephrology consultation, with a decrease in AUC with
removal of nephrology consultation (AUC: 0.645).
Previous studies have shown NGAL’s association with
adverse events (27–29). In the GALLANT study, plasma
NGAL at discharge was shown to predict 30-dayreadmission for AHF and all-cause mortality, with an
AUC of 0.73, which is similar to the AUC in AKINESIS
(27). Furthermore, when grouping patients by eGFR
and first NGAL values, we saw a stepwise increase in
adverse events, as previously reported (28,30).
An exploratory finding was the low rate of adverse
outcomes in subjectswith an eGFR<60ml/min/1.73m2
and NGAL <150 ng/dl, suggesting a possible role for
NGAL (Central Illustration). However, this is a post hoc
subgroup analysis, and is only hypothesis-generating.
Further study is needed to see if this is a specific
population for which NGAL can risk stratify.
Our study has multiple strengths. It is one of the
largest prospective cohorts specifically studying
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Deterioration of renal function has prognostic impor-
tance in patients with AHF, but a rise in the serum
creatinine level is neither timely nor specific. Plasma
levels of NGAL increase in acute kidney injury, and are
associated with adverse outcomes in patients with
chronic HF, but were no better than creatinine levels
in predicting WRF from diuretic therapy or adverse in-
hospital events in patients with AHF.
TRANSLATIONAL OUTLOOK: Further studies are
needed to evaluate the value of biomarkers other than
NGAL for predicting worsening renal function during
diuretic therapy of patients with AHF.
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use tubular biomarkers to predict WRF and its
complications in AHF, we might need to consider
more robust definitions of WRF, including larger
changes in creatinine over longer periods of time
before improvement occurs, and the association
with extraneous factors, such as continued use of
angiotensin-converting enzyme inhibitors or other
superimposed inflammatory conditions. Our data
support the notion of Damman and Testani (7) that
much of the creatinine elevation in AHFmay be termed
pseudo-WRF.
STUDY LIMITATIONS. Samples were collected after
diuretic therapy was administered, in part, to not
delay treatment, but this may have influenced NGAL
levels. Samples were only collected early during the
hospitalization, because the intent was to assess the
development of early WRF. The first measured
creatinine value was used as the baseline for assess-
ment of WRF; however, this value may have already
been elevated from a patient’s baseline creatinine.
Patients may have been experiencing WRF on
admission not secondary to IV diuretic agents. In
addition, creatinine measurements were not per-
formed at a core laboratory and are subject to
between-laboratory variability.
For outcomes, different definitions of WRF and
adverse outcomes could have been used; however,
analysis with alternative WRF definitions did not
improve NGAL diagnostic utility. Our endpoints were
on the basis of published reports at the time of
inception of AKINESIS, and additional exploratory
analyses have been prompted by recent changes in
the understanding of WRF (22–24). Although in-
hospital outcomes were closely monitored, events
were not centrally validated. No interaction was
found between NGAL and region; however, unmea-
sured differences in delivery of care between the
United States and Europe still could have influenced
results. Lastly, we lack post-discharge outcomes inthis analysis, which could have implications for the
utility of NGAL.
CONCLUSIONS
AKINESIS is a novel, large, multicenter cohort study
exploring new biomarkers for AKI in AHF. AKINESIS
does not support the routine use of NGAL for earlier
detection of WRF or need for RRT in patients
admitted with AHF and treated with diuretic agents.
Also, NGAL overall was no more predictive of adverse
outcomes than creatinine. There was a signal
that a low NGAL value in patients with an eGFR
<60 ml/min/1.73 m2 was sensitive for predicting a
low risk of adverse outcomes; however, this is only
hypothesis-generating.
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